Abstract
An apixaban (APX) amorphous solid dispersion (ASD) containing hydroxypropyl methylcellulose (HPMC) and D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) was prepared by spray drying to improve solubility and oral exposure. Screening identified HPMC for supersaturation maintenance and TPGS for apparent solubilization. A central composite design optimized their ratios using five responses: supersaturation solubility, 30-min kinetic solubility, kinetic solubility area under the curve (AUC), particle size, and polydispersity index (PDI). The optimized APX/HPMC/TPGS ratio was 1:3.93:0.85 (w/w/w), with a composite desirability of 0.8491 (on a scale from 0 to 1). Compared with crystalline APX, the optimized ASD increased supersaturation solubility, 30-min kinetic solubility, and kinetic solubility AUC 4.04-, 5.47-, and 8.10-fold, respectively. The dispersed formulation exhibited a particle size of 203.4 ± 17.3 nm and PDI of 0.246 ± 0.018. PXRD and DSC supported predominantly amorphous APX, while electron microscopy and DLS supported nanosized colloidal particle formation. The optimized ASD also maintained higher kinetic solubility in fasted-state simulated intestinal fluid than crystalline and amorphous APX. In rats, Cmax, AUC0–24, and AUC0–inf increased by 2.46-, 3.04-, and 2.80-fold, respectively, versus crystalline APX.

This publication has 41 references indexed in Scilit: